附属病院
附属病院
English
更新日：2025/02/07
助教
ﾏﾙﾀ　ﾏｻｷ
丸田　雅樹

所属

  1. 愛媛大学医学部附属病院助教
  2. 愛媛大学医学部附属病院助教

経歴

  1. 2011/04-2013/03市立宇和島病院
  2. 2013/04-2015/03市立宇和島病院専攻医
  3. 2015/04-2019/12愛媛大学医学部 医学科医員
  4. 2020/01-現在愛媛大学医学部附属病院助教

学歴

  1. 愛媛大学2005/042011/03
  2. 愛媛大学2015/042019/10

学位

  1. 医学博士愛媛大学医学部

免許・資格

  1. 医師免許
  2. 認定内科医
  3. 血液内科専門医
  4. がん薬物療法専門医
  5. がん治療認定医
  6. 血液内科指導医

研究分野

  1. ライフサイエンス血液、腫瘍内科学がん薬物療法
  2. ライフサイエンス感染症内科学臨床感染症

書籍等出版物

  1. 【急性骨髄性白血病(AML)診療の現状と進展】AMLに対する免疫療法の可能性丸田 雅樹 谷本 一史 藤原 弘(有)科学評論社2018/02
  2. 【腫瘍免疫と癌免疫療法】遺伝子改変T細胞による癌免疫療法丸田 雅樹 藤原 弘(有)科学評論社2017/12
  3. 【血液腫瘍に対する免疫療法の新たな展開】ATLに対するmogamulizumab併用遺伝子修飾T細胞療法の可能性藤原 弘 丸田 雅樹(有)科学評論社2017/01
詳細表示...

論文

  1. Reinforced anti-myeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with Bridging-BiTE2023/09/22Tatsuya Konishi Toshiki Ochi Masaki Maruta Kazushi Tanimoto Yukihiro Miyazaki Chika Iwamoto Takashi Saitou Takeshi Imamura Masaki Yasukawa Katsuto TakenakaBlood Journal研究論文（学術雑誌）10.1182/blood.2022019082URLAmerican Society of HematologyImmunotherapy using bispecific antibodies including bispecific T-cell engager (BiTE) has the potential to enhance the efficacy of treatment for relapsed/refractory multiple myeloma. However, myeloma may still recur after treatment due to downregulation of a target antigen and/or myeloma cell heterogeneity. To strengthen immunotherapy for myeloma while overcoming its characteristics, we have newly developed a BiTE-based modality, referred to as Bridging-BiTE (B-BiTE). B-BiTE was able to bind to both a human IgG-Fc domain and the CD3 molecule. Clinically available monoclonal antibodies (mAbs) were bound with B-BiTE prior to administration, and the mAb/B-BiTE complex induced antitumor T-cell responses successfully while preserving and supporting NK-cell reactivity, resulting in enhanced anti-myeloma effects via dual-lymphoid activation. In contrast, any unwanted off-target immune-cell reactivity mediated by mAb/B-BiTE complexes, or B-BiTE itself, appeared not to be observed in vitro and in vivo. Importantly, sequential immunotherapy using two different mAb/B-BiTE complexes appeared to circumvent myeloma cell antigen escape, and further augmented immune responses to myeloma relative to those induced by mAb/B-BiTE monotherapy or sequential therapy with two mAbs in the absence of B-BiTE. Therefore, this modality facilitates easy and prompt generation of a broad panel of bispecific antibodies that can induce deep and durable antitumor responses in the presence of clinically available mAbs, supporting further advancement of reinforced immunotherapy for multiple myeloma and other refractory hematological malignancies.
  2. COVID-19発症後に4ヵ月以上SARS-CoV-2の持続排出を認めた同種造血幹細胞移植患者2023/04宮崎 幸大 末盛 浩一郎 桑原 希 谷口 裕美 村上 忍 小西 達矢 名部 彰悟 丸田 雅樹 越智 俊元 谷本 一史 宮本 仁志 山之内 純 岩城 洋己 四宮 博人 竹中 克斗日本造血・免疫細胞療法学会雑誌12/ 2, 129-132(一社)日本造血・免疫細胞療法学会
  3. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.2022/11/23Tomotaka Suzuki Dai Maruyama Ryunosuke Machida Tomoko Kataoka Noriyasu Fukushima Nobuyuki Takayama Rie Ohba Ken Omachi Yoshitaka Imaizumi Masahito Tokunaga Hiroo Katsuya Isao Yoshida Kazutaka Sunami Mitsutoshi Kurosawa Nobuko Kubota Hiroaki Morimoto Miki Kobayashi Kazuhito Yamamoto Yoshihiro Kameoka Yoshitoyo Kagami Takayuki Tabayashi Masaki Maruta Tsutomu Kobayashi Shinsuke Iida Hirokazu NagaiHematological oncology10.1002/hon.3103The UK Myeloma Research Alliance Risk Profile (MRP) is a novel prognostic model for transplant-ineligible patients with multiple myeloma (MM). Since MRP was developed based on the results of clinical trials in which immunomodulatory drugs were used as induction regimens, its applicability to patients treated with bortezomib-based regimens remains elusive. The aim of this study is to assess the utility of MRP in patients treated with a representative bortezomib-based regimen of melphalan, prednisolone, and bortezomib (MPB) in JCOG1105, a randomized phase II trial comparing two modified MPB regimens. The patients (n=88) were categorized into MRP risk of low (59%), medium (18%), and high (23%). The median follow-up time was 3.9 years, and a higher MRP risk was not associated with poor overall survival (p=0.45). The 3-year OS of patients with low-, medium-, and high-risk of MRP was 84.3% (95% confidence interval [CI], 71.1-91.8%), 68.8% (95% CI, 40.5-85.6%), and 85.0% (95% CI, 60.4-94.9%), respectively. In conclusion, higher MRP risk groups were not significantly associated with poor prognosis in patients who received an MPB regimen in this supplementary analysis of JCOG1105. Large-scale studies which include patients treated with bortezomib-based regimens are required to further validate the significance of the MRP. This article is protected by copyright. All rights reserved.
  4. 皮疹を契機に慢性骨髄単球性白血病と診断しえた皮下型Sweet症候群の1例2022/08岩田 麻里 吉田 論 丸田 雅樹 近藤 厚敏 武藤 潤 佐山 浩二西日本皮膚科84/ 4日本皮膚科学会-西部支部
  5. 剖検時の細菌学的検査（PMM；postmortem microbiology）により主たる死因を証明し得た骨髄異形成症候群2022/07/20丸田 雅樹, 末盛 浩一郎, 谷脇 真潮, 村上 忍, 福島 万奈, 加藤 潤一, 木原 久文, 名部 彰悟, 池田 祐一, 越智 俊元, 波呂 卓, 谷本 一史, 竹内 一人, 山之内 純, 宮本 仁志, 竹中 克斗感染症学雑誌96/ 4, 148-153URL一般社団法人 日本感染症学会<p>A 69-year-old male was admitted to Ehime University Hospital with bicytopenia. He was diagnosed with myelodysplastic syndrome (MDS) and was administered chemotherapy. He was a multimorbid patient with chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), type 2 diabetes, and Sweet's disease resulting in a skin rash. The patient was treated with oral prednisolone for Sweet's syndrome, and cefepime infusions for pneumonia that arose during the first course of chemotherapy. Both of these complications were almost recovered on physical and image findings. During the second course of chemotherapy, he developed Kytococcus schroeteri bacteremia that was successfully treated with linezolid and meropenem infusions, but he died owing to Stenotrophomonas maltophilia bacteremia that occurred 6 h after the K. schroeteri bacteremia. Postmortem microbiology (PMM) proved his reservoir of S. maltophilia bacteremia as pneumonia. There are only 20 reports of K. schroeteri bacteremia in the Medline database. According to our knowledge, this is the first case that developed K. schroeteri and S. maltophilia bacteremia sequentially. In addition, this case highlights the importance of PMM in improving treatment of infectious diseases.</p>
詳細表示...

講演・口頭発表等

  1. キメラ抗原受容体導入T細胞の機能におけるCD4分子の役割臨床血液2023/06
  2. 新型コロナウイルスワクチン接種後に発症した後天性血友病Aの2症例臨床血液2023/06
  3. ベネトクラクス・アザシチジン療法で治療を行った急性巨核芽球性白血病臨床血液2023/06
  4. Probiotic-related Clostridium butyricum bacteremia in an allogeneic HSCT recipient第84回日本血液学会総学術集会2022/10/15
  5. 多発脳梗塞を伴う再発性血管内大細胞型B細胞性リンパ腫に対してポラツズマブの投与が有効であった1例臨床血液2022
詳細表示...

受賞

  1. 2021/11/22指導医奨励賞Kytococcus schroeteriとStenotrophomonas maltophiliaによる菌血症を発症し、冒険で感染巣を証明し得た骨髄異形成症候群
  2. 2017/05Best Poster Presentation AwardStrategically Comprehensive Immunotherapy Utilizing Modified Antibody Targeting NY-ESO-1 for Myeloma
詳細表示...

担当授業科目

  1. 2023血液内科学
  2. 2023がん化学療法総論
詳細表示...

教育実績

  1. 愛媛大学医学部　臨床研修指導医講習会　タスクフォース教育方法・教育実践に関する発表、講演等2023/08/05-2023/08/06
  2. 第18回医学部Best Teacher賞教育上の能力に関する大学等の評価2023/01/27
  3. 愛媛県立中央病院 臨床研修指導医講習会 タスクフォース教育方法・教育実践に関する発表、講演等2023/01/21-2023/01/22
  4. 愛媛大学医学部　臨床研修指導医講習会　タスクフォース教育方法・教育実践に関する発表、講演等2022/07/23-2022/07/24
  5. 第17回医学部Best Teacher賞教育上の能力に関する大学等の評価2022/01/27
詳細表示...

メディア報道

  1. イシュラン血液がんwarm30 (2022)インターネットメディア2023/01/23患者によるがん化学療法専門医の評価サイトにおいて、患者とのコミュニケーションが良好な医師に選定
詳細表示...

所属学協会

  1. 2021/04/01日本造血・免疫細胞療法学会
  2. 2020/04-現在日本がんサポーティブケア学会
  3. 2017/04-現在日本癌学会
  4. 2013-現在日本血液学会
  5. 2012-現在日本感染症学会
詳細表示...

担当経験のある科目

  1. 臨床腫瘍学集中講義2020/10-現在
詳細表示...